National Academies Press: OpenBook
« Previous: Appendix G: Health Care Reform Legislation
Suggested Citation:"Appendix H: Acronyms." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 248
Suggested Citation:"Appendix H: Acronyms." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 249
Suggested Citation:"Appendix H: Acronyms." Institute of Medicine. 1995. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: The National Academies Press. doi: 10.17226/4906.
×
Page 250

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix H Acronyms AAPAA American Academy of Psychiatrists in Alcoholism and Addiction ABMS American Board of Medical Specialties ABPN American Board of Psychiatry and Neurology ACTH adrenocorticotrophic hormone ADAMHA Alcohol, Drug Abuse, and Mental Health Administration ADD Antiepileptic Drug Development Program ADEPT Alcohol and Drug Education for Physician Training AFDC Aid to Families with Dependent Children AIDS acquired immune deficiency syndrome ALS amyotrophic lateral sclerosis (Lou Gehrig's disease) AMBHA American Managed Behavioral Healthcare Association AMERSA Association for Medical Education and Research in Substance Abuse AMP adenosine 3'5'-monophosphate ASAM American Society of Addiction Medicine ATC addiction training center AZT zidovudine BDC BioDevelopment Corporation BJS Bureau of Justice Statistics BLS Bureau of Labor Statistics BSMD Biobehavioral Sciences and Mental Disorders CALDATA California Drug and Alcohol Treatment Assessment CASA Center on Addiction and Substance Abuse CBO Congressional Budget Office 248

APPENDIX H 249 CDC Centers for Disease Control and Prevention CDDA Commission on Medicines for Treatment of Drug Dependence and Abuse CDER Center for Drug Evaluation and Research CDP chemical dependency programs CME continuing medical education CMHS Center for Mental Health Services CNS central nervous system CPDD College on Problems of Drug Dependence CRADAs cooperative research and development agreements CRS Congressional Research Service CSA Controlled Substances Act CSAP Center for Substance Abuse Prevention CSAT Center for Substance Abuse Treatment CTDP Cocaine Treatment Discovery Program DAWN Drug Abuse Warning Network DD drug-discrimination test DEA Drug Enforcement Agency DHHS U.S. Department of Health and Human Services DPC-PTR Drug Price Competition and Patent Term Restoration Act DSRS Drug Services Research Survey DVA Department of Veterans Affairs FDA Food and Drug Administration FDCA Federal Food, Drug, and Cosmetic Act FTEs full-time equivalent personnel FY fiscal year GAO General Accounting Office HIV human immunodeficiency virus HMO health maintenance organization HRSA Health Resources and Services Administration IDU injecting drug-user IND investigational new drug IOM Institute of Medicine IRE institutional review board K20 Scientist Development Award for Clinicians K21 Scientist Development Award LAAM levo-alpha-acetylmethadol (trade name ORLAAM) LMA locomotor-activity test LRP Loan Repayment Program MARC Minority Access to Research Careers MDD Medications Development Division MDMA Methylenedioxymethamphetamine ("ecstacy")

250 DEVELOPMENT OF MEDICATIONS MSH melanocyte-stimulating hormone NAS National Academy of Sciences NASADAD National Association of State Alcohol and Drug Abuse Directors, Inc. NATA Narcotic Addict Treatment Act NCDDG-AIDS National Cooperative Drug Discovery Groups on Acquired Immune Deficiency Syndrome NCI National Cancer Institute NCJA National Criminal Justice Association NDA new drug application NDATUS National Drug and Alcoholism Treatment Survey NIAAA National Institute on Alcohol Abuse and Alcoholism Administration NIAID National Institute of Allergy and Infectious Diseases NIDA National Institute on Drug Abuse NIH National Institutes of Health NRC National Research Council NRSA National Research Service Awards ODE out-patient drug-free ONDCP Office of National Drug Control Policy OPRR Office of Protection from Research Risks ORLAAMrM levo-alpha-acetylmethadol (LAAM) OTA Office of Technology Assessment PBMs pharmaceutical benefit managers PCP phencyclidine PhRMA Pharmaceutical Research and Manufacturers of America PHS Public Health Service PMA Pharmaceutical Manufacturers Association POMC pro-opiomelanocortin R&D research and development R01 investigator-initiated grants R18 research-demonstration grants SA self-administration test SADAP State Alcohol and Drug Abuse Profile SAMHSA Substance Abuse and Mental Healtn Services Administration SSI Supplemental Security Income TB tuberculosis Tcs therapeutic communities TOPS Treatment Outcome Prospective Study TRUs treatment research units VA Department of Veterans Affairs WHO World Health Organization

The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector Get This Book
×
Buy Paperback | $54.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Pharmacotherapy, as a means of treating drug addiction in combination with other treatment modalities, has received too little attention from the research community, the pharmaceutical industry, public health officials, and the federal government. Medications to combat drug addiction could have an enormous impact on the medical consequences and socioeconomic problems associated with drug abuse, both for drug-dependent individuals and for American society as a whole. This book examines the current environment for and obstacles to the development of anti-addiction medications, specifically those for treating opiate and cocaine addictions, and proposes incentives for the pharmaceutical industry that would help overcome those obstacles and accelerate the development of anti-addiction medications.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!